Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia
A systematic review was conducted to examine the associations in Pneumocystis jirovecii pneumonia (PCP) patients between dihydropteroate synthase (DHPS) mutations and sulfa or sulfone (sulfa) prophylaxis and between DHPS mutations and sulfa treatment outcome. Selection criteria included study popula...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Centers for Disease Control and Prevention
2004-10-01
|
Series: | Emerging Infectious Diseases |
Subjects: | |
Online Access: | https://wwwnc.cdc.gov/eid/article/10/10/04-0362_article |
id |
doaj-ab1953f5e826417cb8e214677e55e5a7 |
---|---|
record_format |
Article |
spelling |
doaj-ab1953f5e826417cb8e214677e55e5a72020-11-25T00:30:56ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592004-10-0110101760176510.3201/eid1010.040362Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii PneumoniaCheryl R. SteinCharles PoolePowel KazanjianSteven R MeshnickA systematic review was conducted to examine the associations in Pneumocystis jirovecii pneumonia (PCP) patients between dihydropteroate synthase (DHPS) mutations and sulfa or sulfone (sulfa) prophylaxis and between DHPS mutations and sulfa treatment outcome. Selection criteria included study populations composed entirely of PCP patients and mutation or treatment outcome results for all patients, regardless of exposure status. Based on 13 studies, the risk of developing DHPS mutations is higher for PCP patients receiving sulfa prophylaxis than for PCP patients not receiving sulfa prophylaxis (p < 0.001). Results are too heterogeneous (p < 0.001) to warrant a single summary effect estimate. Estimated effects are weaker after 1996 and stronger in studies that included multiple isolates per patient. Five studies examined treatment outcome. The effect of DHPS mutations on treatment outcome has not been well studied, and the few studies that have been conducted are inconsistent even as to the presence or absence of an association.https://wwwnc.cdc.gov/eid/article/10/10/04-0362_articledihydropteroate synthasemeta-analysisPneumocystisPneumocystis cariniitrimethoprim-sulfamethoxazole combination (sulfa drugs)treatment failure |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cheryl R. Stein Charles Poole Powel Kazanjian Steven R Meshnick |
spellingShingle |
Cheryl R. Stein Charles Poole Powel Kazanjian Steven R Meshnick Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia Emerging Infectious Diseases dihydropteroate synthase meta-analysis Pneumocystis Pneumocystis carinii trimethoprim-sulfamethoxazole combination (sulfa drugs) treatment failure |
author_facet |
Cheryl R. Stein Charles Poole Powel Kazanjian Steven R Meshnick |
author_sort |
Cheryl R. Stein |
title |
Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia |
title_short |
Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia |
title_full |
Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia |
title_fullStr |
Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia |
title_full_unstemmed |
Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia |
title_sort |
sulfa use, dihydropteroate synthase mutations, and pneumocystis jirovecii pneumonia |
publisher |
Centers for Disease Control and Prevention |
series |
Emerging Infectious Diseases |
issn |
1080-6040 1080-6059 |
publishDate |
2004-10-01 |
description |
A systematic review was conducted to examine the associations in Pneumocystis jirovecii pneumonia (PCP) patients between dihydropteroate synthase (DHPS) mutations and sulfa or sulfone (sulfa) prophylaxis and between DHPS mutations and sulfa treatment outcome. Selection criteria included study populations composed entirely of PCP patients and mutation or treatment outcome results for all patients, regardless of exposure status. Based on 13 studies, the risk of developing DHPS mutations is higher for PCP patients receiving sulfa prophylaxis than for PCP patients not receiving sulfa prophylaxis (p < 0.001). Results are too heterogeneous (p < 0.001) to warrant a single summary effect estimate. Estimated effects are weaker after 1996 and stronger in studies that included multiple isolates per patient. Five studies examined treatment outcome. The effect of DHPS mutations on treatment outcome has not been well studied, and the few studies that have been conducted are inconsistent even as to the presence or absence of an association. |
topic |
dihydropteroate synthase meta-analysis Pneumocystis Pneumocystis carinii trimethoprim-sulfamethoxazole combination (sulfa drugs) treatment failure |
url |
https://wwwnc.cdc.gov/eid/article/10/10/04-0362_article |
work_keys_str_mv |
AT cherylrstein sulfausedihydropteroatesynthasemutationsandpneumocystisjiroveciipneumonia AT charlespoole sulfausedihydropteroatesynthasemutationsandpneumocystisjiroveciipneumonia AT powelkazanjian sulfausedihydropteroatesynthasemutationsandpneumocystisjiroveciipneumonia AT stevenrmeshnick sulfausedihydropteroatesynthasemutationsandpneumocystisjiroveciipneumonia |
_version_ |
1725324913697357824 |